These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 19566934

  • 21. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
    Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, Quinn M, Lu C, Young D, Cameron R, Bucchioni E, Altman P.
    Eur Respir J; 2014 Dec; 44(6):1548-56. PubMed ID: 25359348
    [Abstract] [Full Text] [Related]

  • 22. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 23. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 Dec; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 24. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
    Calverley PMA, Stockley RA, Seemungal TAR, Hagan G, Willits LR, Riley JH, Wedzicha JA, Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators.
    Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
    [Abstract] [Full Text] [Related]

  • 25. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A, Vilariño Pombo C.
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [Abstract] [Full Text] [Related]

  • 26. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C, Keating GM.
    Drugs; 2004 Mar; 64(17):1975-96. PubMed ID: 15329047
    [Abstract] [Full Text] [Related]

  • 27. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 28. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S.
    Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
    [Abstract] [Full Text] [Related]

  • 29. Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients.
    Johnson M, Agusti AG, Barnes NC.
    COPD; 2008 Dec; 5(6):369-75. PubMed ID: 19353351
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 31. The TORCH (towards a revolution in COPD health) survival study protocol.
    Vestbo J, TORCH Study Group.
    Eur Respir J; 2004 Aug; 24(2):206-10. PubMed ID: 15332386
    [Abstract] [Full Text] [Related]

  • 32. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, SUMMIT Investigators.
    Lancet; 2016 Apr 30; 387(10030):1817-26. PubMed ID: 27203508
    [Abstract] [Full Text] [Related]

  • 33. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug 30; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

  • 34. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ, Cates CJ, Poole P.
    Cochrane Database Syst Rev; 2013 May 31; (5):CD007891. PubMed ID: 23728670
    [Abstract] [Full Text] [Related]

  • 35. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 31; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 36. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA, Hawes HG, Doig CJ, Johnson MW, Yokoba M, Wilde ER.
    Chest; 2010 Mar 31; 137(3):558-65. PubMed ID: 19820074
    [Abstract] [Full Text] [Related]

  • 37. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2017 Mar 31; 12():339-349. PubMed ID: 28176893
    [Abstract] [Full Text] [Related]

  • 38. Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.
    Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT.
    Respir Res; 2014 Sep 24; 15(1):105. PubMed ID: 25248764
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y.
    Am J Manag Care; 2009 Apr 24; 15(4):226-32. PubMed ID: 19355795
    [Abstract] [Full Text] [Related]

  • 40. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.